Corpus Intelligence IC Memo — INTERMOUNTAIN 2026-04-26 03:45 UTC
IC Memo — INTERMOUNTAIN
Investment Committee Memorandum | ID | 150 beds | Grade C | EBITDA uplift $2.3M
🛡️ Public data only — no PHI permitted on this instance.
Investment Committee Memorandum

INTERMOUNTAIN

CCN 134002 | ADA, ID | 150 beds | April 26, 2026
EBITDA BridgeData Room
C
Investability

1. Target Overview & Investment Thesis

INTERMOUNTAIN is a 150-bed safety-net/medicaid heavy in ADA, ID with $31.5M in net patient revenue and a 26.3% operating margin. The hospital serves a payer mix of 12.2% Medicare, 45.4% Medicaid, and 42.5% commercial.

Thesis: Turnaround. Our ML models identify $2.3M in annual EBITDA improvement potential from RCM optimization across 5 levers, lifting margin from 26.3% to 33.7% (+736bps).

Net Revenue HCRIS$31.5M
Current EBITDA COMPUTED$8.3M
Operating Margin COMPUTED26.3%
Occupancy HCRIS58.8%
Revenue / Bed COMPUTED$210K
Net-to-Gross HCRIS25.0%
Distress Probability ML56.8%

2. Market Context & Competitive Position

51
ID Hospitals
-3.5%
State Median Margin
10
Comparable Hospitals

ID has 51 Medicare-certified hospitals with a median operating margin of -3.5%. The target's margin of 26.3% places it above the state median. Among 10 size-comparable peers (75-300 beds), the median margin is 5.2%. The target performs in line with or above peers.

3. RCM Performance Analysis — Comparable Hospitals

Comps selected by bed count (75-300), prioritizing same-state peers. 10 hospitals in the comp set.

HospitalStateBedsRevenueMargin
INTERMOUNTAIN (Target)ID150$31.5M26.3%
ST LUKES MAGIC VALLEY REG MED ID175$482.9M-6.8%
PORTNEUF MEDICAL CENTERID142$390.3M13.4%
EASTERN IDAHO REGIONAL MEDICALID233$370.5M42.0%
ST. ALPHONSUS MEDICAL CENTER -ID96$263.3M15.2%
ST. LUKES NAMPA MEDICAL CENTERID87$255.6M-10.1%
ST JOSEPH REGIONAL MEDICAL CENID110$168.4M-3.0%
WEST VALLEY MEDICAL CENTERID112$118.1M24.6%
IDAHO FALLS COMMUNITY HOSPITALID88$98.9M-23.1%

4. Predicted Improvement Opportunities

Improvement targets set at P75 of comparable peers with 60% gap closure assumption. Coefficients calibrated to published research bands. Total EBITDA uplift: $2.3M (736bps margin improvement).

LeverCurrentTargetEBITDA ImpactMarginRamp
Net Collection Rate93.5%97.0%$662K+210bp18mo
Cost to Collect4.5%2.5%$630K+200bp12mo
Denial Rate Reduction12.0%6.5%$624K+198bp12mo
A/R Days Reduction5200.0%3800.0%$383K+122bp9mo
Clean Claim Rate88.0%96.0%$20K+6bp6mo

5. EBITDA Bridge

Net Collection Rate
$662K
Cost to Collect
$630K
Denial Rate Reduction
$624K
A/R Days Reduction
$383K
Clean Claim Rate
$20K
Total EBITDA Uplift$2.3M
Current EBITDA$8.3M
+ RCM Uplift+$2.3M
Pro Forma EBITDA$10.6M
Current Margin26.3%
Pro Forma Margin33.7%
WC Released (1x)$1.2M

6. Returns Analysis — Scenario Matrix

5-year hold, 5.5x leverage, 3% organic growth, 10%/yr debt paydown. Base case uses 100% of predicted RCM uplift. Bull case: 130% uplift at lower entry. Bear case: 50% uplift at higher entry.

ScenarioEntryExitEquity InEquity OutMOICIRR
Base Case10.0x10.0x$12.7M$77.8M6.11x43.6%
Base (11x exit)10.0x11.0x$12.7M$89.7M7.04x47.8%
Bull Case9.0x11.0x$11.5M$101.5M8.85x54.7%
Bull (12x exit)9.0x12.0x$11.5M$114.1M9.95x58.3%
Bear Case11.0x10.0x$14.0M$62.1M4.43x34.7%
Bear (11x exit)11.0x11.0x$14.0M$72.8M5.20x39.1%

7. Key Risks & Mitigants

SeverityRisk FactorMitigant
MediumElevated Medicaid exposure (45.4%)Medicaid reimburses below cost in most states. Mitigant: denial reduction lever has highest impact on Medicaid claims
HighElevated distress probabilityModel estimates 56.8% probability of financial distress. Mitigant: distressed entry pricing (7-9x) compensates for risk

8. Data Sources & Methodology Appendix

Data Sources

  • CMS HCRIS Cost Reports (Medicare-certified hospitals)
  • CMS Medicare Utilization (DRG-level volumes)
  • CMS Chronic Conditions (county-level disease prevalence)
  • HCRIS multi-year trend data (financial time series)

Comparable Selection

  • 10 hospitals with 75-300 beds
  • Same-state prioritization (n=11)
  • Comp margins: P25=-9.3% / P50=5.2% / P75=14.9%

Bridge Methodology

  • Targets: P75 of comparable peers (60% gap closure)
  • Denial: avoidable share = 35% of delta × NPR
  • AR: bad debt coefficient = $0.65 per day per $1K NPR
  • NCR: 60% coefficient on collection rate improvement
  • CDI: 0.75% of Medicare revenue per 0.01 CMI point

Returns Assumptions

  • Leverage: 5.5x entry (84.6% debt / 15.4% equity)
  • Organic growth: 3% annual EBITDA growth
  • Debt paydown: 10% of principal per year
  • Hold period: 5 years

Generated by SeekingChartis on April 26, 2026. All predictions use public data only. Confidence intervals calibrated via split conformal prediction (90% coverage target). This memo is for informational purposes and does not constitute investment advice.